{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:38:15Z","timestamp":1785404295954,"version":"3.56.0"},"reference-count":90,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Heart failure (HF) is one of the most difficult challenges in cardiology nowadays, constituting a significant global epidemiological, social and economic burden. For many years, there has been a search for new risk factors that predispose to the development of HF and biomarkers that could indicate HF patients with a poorer prognosis. Lipoprotein(a) (Lp[a]) is an estimated risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis, but its causal role in HF has not been clearly defined yet. The results of the few studies regarding the influence of elevated Lp(a) on the development and course of HF are uncertain. However, most authors suggest that elevated Lp(a) increases the risk of HF and may correlate with a higher risk of major adverse cardiovascular events. The aim of this review is to present the current state of knowledge on the importance of the association between Lp(a) levels and HF, from pathophysiology to clinical practice including current management.<\/jats:p>","DOI":"10.15420\/cfr.2025.46","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:35:38Z","timestamp":1776443738000},"source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a): A Novel Risk Factor for Heart Failure and Biomarker of Prognosis? From Pathophysiology to Clinical Practice"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7491-9533","authenticated-orcid":false,"given":"Anna","family":"Kowalczys","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019sbgd69","id-type":"ROR","asserted-by":"publisher"}],"name":"Gda\u0144sk Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4981-0226","authenticated-orcid":false,"given":"Joanna","family":"Marl\u0119ga-Linert","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019sbgd69","id-type":"ROR","asserted-by":"publisher"}],"name":"Gda\u0144sk Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-2291","authenticated-orcid":false,"given":"Marcin","family":"Grucha\u0142a","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019sbgd69","id-type":"ROR","asserted-by":"publisher"}],"name":"Gda\u0144sk Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1707-3807","authenticated-orcid":false,"given":"Agnieszka","family":"Mickiewicz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019sbgd69","id-type":"ROR","asserted-by":"publisher"}],"name":"Gda\u0144sk Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"ref0","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484; PMID: 34458905."},{"key":"ref1","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID: 34447992."},{"key":"ref2","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195; PMID: 37622666."},{"key":"ref3","unstructured":"Asocjacja Niewydolno\u015bci Serca Polskiego Towarzystwa Kardiologicznego. Heart Failure in Poland 2014\u20132021. Report [in Polish]. 2023. https:\/\/www.niewydolnosc-serca.pl\/doc\/ANS_raport_01.09_.pdf (accessed 22 May 2025)."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52\u201360. https:\/\/doi.org\/10.1172\/JCI115855; PMID: 1386087. DOI: 10.1172\/JCI115855","DOI":"10.1172\/JCI115855"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361; PMID: 36036785. DOI: 10.1093\/eurheartj\/ehac361","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022;42:e48\u201360. https:\/\/doi.org\/10.1161\/ATV.0000000000000147; PMID: 34647487. DOI: 10.1161\/ATV.0000000000000147","DOI":"10.1161\/ATV.0000000000000147"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2021;37:1129\u201350. https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016; PMID: 33781847. DOI: 10.1016\/j.cjca.2021.03.016","DOI":"10.1016\/j.cjca.2021.03.016"},{"key":"ref8","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. J Am Coll Cardiol 2018;73:3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002; PMID: 30423391."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Wang S, Zha L, Chen J, et al. The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis. Eur J Med Res 2022;27:211. https:\/\/doi.org\/10.1186\/s40001-022-00825-6; PMID: 36303257. DOI: 10.1186\/s40001-022-00825-6","DOI":"10.1186\/s40001-022-00825-6"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol 2019;73:2150\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.070; PMID: 31047003. DOI: 10.1016\/j.jacc.2019.01.070","DOI":"10.1016\/j.jacc.2019.01.070"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017;69:692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042; PMID: 28183512. DOI: 10.1016\/j.jacc.2016.11.042","DOI":"10.1016\/j.jacc.2016.11.042"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol 2022;79:757\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.058; PMID: 35210030. DOI: 10.1016\/j.jacc.2021.11.058","DOI":"10.1016\/j.jacc.2021.11.058"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Arsenault BJ, Boekholdt SM, Dub\u00e9 MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 2014;7:304\u201310. https:\/\/doi.org\/10.1161\/CIRCGENETICS.113.000400; PMID: 24704946. DOI: 10.1161\/CIRCGENETICS.113.000400","DOI":"10.1161\/CIRCGENETICS.113.000400"},{"key":"ref14","unstructured":"Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368:503\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1109034; PMID: 23388002."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Wang HP, Zhang N, Liu YJ, et al. Lipoprotein(a), family history of cardiovascular disease, and incidence of heart failure. J Lipid Res 2023;64:100398. https:\/\/doi.org\/10.1016\/j.jlr.2023.100398; PMID: 37276941. DOI: 10.1016\/j.jlr.2023.100398","DOI":"10.1016\/j.jlr.2023.100398"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated lipoprotein(a) and risk of atrial fibrillation: an observational and Mendelian randomization study. J Am Coll Cardiol 2022;79:1579\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.018; PMID: 35450575. DOI: 10.1016\/j.jacc.2022.02.018","DOI":"10.1016\/j.jacc.2022.02.018"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart Fail 2016;4:78\u201387. https:\/\/doi.org\/10.1016\/j.jchf.2015.08.006; PMID: 26656145. DOI: 10.1016\/j.jchf.2015.08.006","DOI":"10.1016\/j.jchf.2015.08.006"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Masson W, Barbagelata L, Lavalle-Cobo A, et al. Lipoprotein(a) and heart failure: a systematic review. Heart Fail Rev 2023;28:1307\u201314. https:\/\/doi.org\/10.1007\/s10741-023-10333-2; PMID: 37466712. DOI: 10.1007\/s10741-023-10333-2","DOI":"10.1007\/s10741-023-10333-2"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci 2024;20:8\u201327. https:\/\/doi.org\/10.5114\/aoms\/183522; PMID: 38414479. DOI: 10.5114\/aoms\/183522","DOI":"10.5114\/aoms\/183522"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Kronenberg F, Mora S, Stroes ESG. Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees. Curr Opin Lipidol 2022;33:342\u201352. https:\/\/doi.org\/10.1097\/MOL.0000000000000855; PMID: 36251423. DOI: 10.1097\/MOL.0000000000000855","DOI":"10.1097\/MOL.0000000000000855"},{"key":"ref21","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455; PMID: 31504418."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2025;46:4359\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190; PMID: 40878289. DOI: 10.1093\/eurheartj\/ehaf919","DOI":"10.1093\/eurheartj\/ehaf919"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"We\u0142nicki M, Gorczyca-G\u0142owacka I, Kap\u0142on-Cie\u015blicka A, et al. Treatment of dyslipidemia in Poland - common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot. Cardiol J 2025;32:107\u201319. https:\/\/doi.org\/10.5603\/cj.103680; PMID: 40162986. DOI: 10.5603\/cj.103680","DOI":"10.5603\/cj.103680"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Lewek J, Sosnowska B, Bielecka-D\u0105browa A, et al. Lipoprotein(a) and other risk factors in dyslipidemic patients with and without heart failure. Arch Med Sci 2024;20:1705\u20139. https:\/\/doi.org\/10.5114\/aoms\/194684; PMID: 39649260. DOI: 10.5114\/aoms\/194684","DOI":"10.5114\/aoms\/194684"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Velavan P, Huan Loh P, Clark A, Cleland JGF. The cholesterol paradox in heart failure. Congest Heart Fail 2007;13:336\u201341. https:\/\/doi.org\/10.1111\/j.1527-5299.2007.07211.x; PMID: 18046092. DOI: 10.1111\/j.1527-5299.2007.07211.x","DOI":"10.1111\/j.1527-5299.2007.07211.x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2003.07.016; PMID: 14662255. DOI: 10.1016\/j.jacc.2003.07.016","DOI":"10.1016\/j.jacc.2003.07.016"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Horwich TB, Hernandez AF, Dai D, et al. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J 2008;156:1170\u20136. https:\/\/doi.org\/10.1016\/j.ahj.2008.07.004; PMID: 19033015. DOI: 10.1016\/j.ahj.2008.07.004","DOI":"10.1016\/j.ahj.2008.07.004"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Li Z, Liu J, Shen J, et al. Association of lipoprotein (a) and 1 year prognosis in patients with heart failure with reduced ejection fraction. ESC Heart Fail 2022;9:2399\u2013406. https:\/\/doi.org\/10.1002\/ehf2.13933; PMID: 35419980. DOI: 10.1002\/ehf2.13933","DOI":"10.1002\/ehf2.13933"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Cai A, Li L, Zhang Y, et al. Lipoprotein(a): a promising marker for residual cardiovascular risk assessment. Dis Markers 2013;35:551\u20139. https:\/\/doi.org\/10.1155\/2013\/563717; PMID: 24249942. DOI: 10.1155\/2013\/563717","DOI":"10.1155\/2013\/563717"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Sosnowska B, Lewek J, Adach W, et al. The prevalence, patients\u2019 characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry. Prog Cardiovasc Dis 2024;86:54\u201361. https:\/\/doi.org\/10.1016\/j.pcad.2024.08.004; PMID: 39191356. DOI: 10.1016\/j.pcad.2024.08.004","DOI":"10.1016\/j.pcad.2024.08.004"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week. J Am Coll Cardiol 2022;80:934\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2022.06.019; PMID: 36007992. DOI: 10.1016\/j.jacc.2022.06.019","DOI":"10.1016\/j.jacc.2022.06.019"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Singh S, Baars DP, Aggarwal K, et al. Association between lipoprotein (a) and risk of heart failure: a systematic review and meta-analysis of Mendelian randomization studies. Curr Probl Cardiol 2024;49:102439. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102439; PMID: 38301917. DOI: 10.1016\/j.cpcardiol.2024.102439","DOI":"10.1016\/j.cpcardiol.2024.102439"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Mora S, Akinkuolie AO, Sandhu RK, et al. Paradoxical association of lipoprotein measures with incident atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:612\u20139. https:\/\/doi.org\/10.1161\/CIRCEP.113.001378; PMID: 24860180. DOI: 10.1161\/CIRCEP.113.001378","DOI":"10.1161\/CIRCEP.113.001378"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Garg PK, Guan W, Karger AB, et al., Lp. Lp(a) (Lipoprotein [a]) and Risk for Incident Atrial Fibrillation: Multi-Ethnic Study of Atherosclerosis. Circ Arrhythm Electrophysiol 2020;13:e008401. https:\/\/doi.org\/10.1161\/CIRCEP.120.008401; PMID: 32302223. DOI: 10.1161\/CIRCEP.120.008401","DOI":"10.1161\/CIRCEP.120.008401"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Shitara J, Kasai T, Konishi H, et al. Impact of lipoprotein (a) levels on long-term outcomes in patients with coronary artery disease and left ventricular systolic dysfunction. Circ J 2019;83:1047\u201353. https:\/\/doi.org\/10.1253\/circj.CJ-18-0970; PMID: 30918220. DOI: 10.1253\/circj.CJ-18-0970","DOI":"10.1253\/circj.CJ-18-0970"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ward NC, Nolde JM, Chan J, et al. Lipoprotein (a) and hypertension. Curr Hypertens Rep 2021;23:44. https:\/\/doi.org\/10.1007\/s11906-021-01161-6; PMID: 34888749. DOI: 10.1007\/s11906-021-01161-6","DOI":"10.1007\/s11906-021-01161-6"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Sorokin A, Kotani K. Lipoprotein(a) and arterial stiffness parameters. Pulse (Basel) 2015;3:148\u201352. https:\/\/doi.org\/10.1159\/000438733; PMID: 26587464. DOI: 10.1159\/000438733","DOI":"10.1159\/000438733"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Marti CN, Gheorghiade M, Kalogeropoulos AP, et al. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 2012;60:1455\u201369. https:\/\/doi.org\/10.1016\/j.jacc.2011.11.082; PMID: 22999723. DOI: 10.1016\/j.jacc.2011.11.082","DOI":"10.1016\/j.jacc.2011.11.082"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Agarwala A, Pokharel Y, Saeed A, et al. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis 2017;262:131\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.05.014; PMID: 28554015. DOI: 10.1016\/j.atherosclerosis.2017.05.014","DOI":"10.1016\/j.atherosclerosis.2017.05.014"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Januzzi JL Jr, van Kimmenade RRJ, Liu Y, et al. Lipoprotein(a), oxidized phospholipids, and progression to symptomatic heart failure: the Casablanca study. J Am Heart Assoc 2024;13:e034774. https:\/\/doi.org\/10.1161\/JAHA.124.034774; PMID: 38860394. DOI: 10.1161\/JAHA.124.034774","DOI":"10.1161\/JAHA.124.034774"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Chehab O, Abdollahi A, Whelton SP, et al. Association of lipoprotein(a) levels with myocardial fibrosis in the multi-ethnic study of atherosclerosis. J Am Coll Cardiol 2023;82:2280\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.016; PMID: 38057070. DOI: 10.1016\/j.jacc.2023.10.016","DOI":"10.1016\/j.jacc.2023.10.016"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:2311\u20136. https:\/\/doi.org\/10.1161\/ATVBAHA.108.179697; PMID: 21084697. DOI: 10.1161\/ATVBAHA.108.179697","DOI":"10.1161\/ATVBAHA.108.179697"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Fasolo F, Jin H, Winski G, et al. Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization. Circulation 2021;144:1567\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052023; PMID: 34647815. DOI: 10.1161\/CIRCULATIONAHA.120.052023","DOI":"10.1161\/CIRCULATIONAHA.120.052023"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"L\u00f3pez B, Ravassa S, Moreno MU, et al. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol 2021;18:479\u201398. https:\/\/doi.org\/10.1038\/s41569-020-00504-1; PMID: 33568808. DOI: 10.1038\/s41569-020-00504-1","DOI":"10.1038\/s41569-020-00504-1"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Lambert G, Chemello K, Gallo A. Lipoprotein(a): more than just a biomarker of myocardial fibrosis. J Am Coll Cardiol 2023;82:2292\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.019; PMID: 38057071. DOI: 10.1016\/j.jacc.2023.10.019","DOI":"10.1016\/j.jacc.2023.10.019"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Khan SS, Lloyd-Jones DM, Abdalla M, et al. Use of risk assessment to guide decision-making for blood pressure management in the primary prevention of cardiovascular disease: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2025;86:1539\u201359. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.001; PMID: 40879587. DOI: 10.1016\/j.jacc.2025.08.001","DOI":"10.1016\/j.jacc.2025.08.001"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. Circulation 2019;140:e596\u2013646. https:\/\/doi.org\/10.1161\/CIR.0000000000000678; PMID: 30879355. DOI: 10.1161\/CIR.0000000000000725","DOI":"10.1161\/CIR.0000000000000725"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Steffen BT, Duprez D, Bertoni AG, et al. Lp(a) [lipoprotein(a)]-related risk of heart failure is evident in whites but not in other racial\/ethnic groups. Arterioscler Thromb Vasc Biol 2018;38:2498\u2013504. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311220; PMID: 30354212. DOI: 10.1161\/ATVBAHA.118.311220","DOI":"10.1161\/ATVBAHA.118.311220"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol 2019;74:2982\u201394. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.019; PMID: 31865966. DOI: 10.1016\/j.jacc.2019.10.019","DOI":"10.1016\/j.jacc.2019.10.019"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Dai K, Shiode N, Yoshii K, et al. Impact of lipoprotein (a) on long-term outcomes in patients with acute myocardial infarction. Circ J 2023;87:1356\u201361. https:\/\/doi.org\/10.1253\/circj.CJ-23-0221; PMID: 37258219. DOI: 10.1253\/circj.CJ-23-0221","DOI":"10.1253\/circj.CJ-23-0221"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Wu B, Zhang Z, Long J, et al. Association between lipoprotein (a) and heart failure with reduced ejection fraction development. J Clin Lab Anal 2022;36:e24083. https:\/\/doi.org\/10.1002\/jcla.24083; PMID: 34850462. DOI: 10.1002\/jcla.24083","DOI":"10.1002\/jcla.24083"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Schrader B, Lorenz F, Weers A, et al. Cardiovascular endpoints and psychosocial challenges of lipoprotein(a) of 5726 participants in the ELITE-study over 5 years. Lipids Health Dis 2025;24:362. https:\/\/doi.org\/10.1186\/s12944-025-02785-2; PMID: 41239477. DOI: 10.1186\/s12944-025-02785-2","DOI":"10.1186\/s12944-025-02785-2"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Liu L, Ma H, Yang S, et al. The role of lipoprotein(a) in cardiovascular risk stratification: integrating low-density lipoprotein cholesterol and polygenic risk scores. Am J Cardiol 2025;259:116\u201322. https:\/\/doi.org\/10.1016\/j.amjcard.2025.09.012; PMID: 41005599. DOI: 10.1016\/j.amjcard.2025.09.012","DOI":"10.1016\/j.amjcard.2025.09.012"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Wu B, Zhao H, Liu C, et al. Association of lipoprotein (a) and in-hospital outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Postgrad Med 2021;133:195\u2013201. https:\/\/doi.org\/10.1080\/00325481.2020.1845517; PMID: 33131368. DOI: 10.1080\/00325481.2020.1845517","DOI":"10.1080\/00325481.2020.1845517"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Zhang X, Niu N, Yu S, et al. The correlation between lipoprotein(a) and major adverse cardiovascular events in patients with acute myocardial infarction combined with heart failure with preserved ejection fraction. Front Cardiovasc Med 2025;12:1515916. https:\/\/doi.org\/10.3389\/fcvm.2025.1515916; PMID: 40552189. DOI: 10.3389\/fcvm.2025.1515916","DOI":"10.3389\/fcvm.2025.1515916"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Wang Y, Ma H, Yang J, et al. Lipoprotein(a) is associated with left ventricular systolic dysfunction in a Chinese population of patients with hypertension and without coronary artery disease. Arch Med Sci 2017;13:1078\u201385. https:\/\/doi.org\/10.5114\/aoms.2016.59875; PMID: 28883849. DOI: 10.5114\/aoms.2016.59875","DOI":"10.5114\/aoms.2016.59875"},{"key":"ref57","unstructured":"Satterfield BA, Dikilitas O, Safarova MS, et al. Associations of genetically predicted Lp(a) (lipoprotein [a]) levels with cardiovascular traits in individuals of European and African ancestry. Circ Genom Precis Med 2021;14:e003354. https:\/\/doi.org\/10.1161\/CIRCGEN.120.003354; PMID: 34282949."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Nomura S, Guan W, Zhang Y, et al. Lipoprotein(a) and heart failure among black and white participants in atherosclerosis risk in communities study, Framingham offspring study, and multi-ethnic study of atherosclerosis: the pooling project. J Am Heart Assoc 2025;14:e038608. https:\/\/doi.org\/10.1161\/JAHA.124.038608; PMID: 40417812. DOI: 10.1161\/JAHA.124.038608","DOI":"10.1161\/JAHA.124.038608"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank. Arterioscler Thromb Vasc Biol 2021;41:465\u201374. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315291; PMID: 33115266. DOI: 10.1161\/ATVBAHA.120.315291","DOI":"10.1161\/ATVBAHA.120.315291"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Berman AN, Biery DW, Besser SA, et al. Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease. J Am Coll Cardiol 2024;83:873\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.031; PMID: 38418000. DOI: 10.1016\/j.jacc.2023.12.031","DOI":"10.1016\/j.jacc.2023.12.031"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Boffa MB, Stranges S, Klar N, et al. Lipoprotein(a) and secondary prevention of atherothrombotic events: a critical appraisal. J Clin Lipidol 2018;12:1358\u201366. https:\/\/doi.org\/10.1016\/j.jacl.2018.08.012; PMID: 30316749. DOI: 10.1016\/j.jacl.2018.08.012","DOI":"10.1016\/j.jacl.2018.08.012"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Yan J, Pan Y, Xiao J, et al. High level of lipoprotein(a) as predictor for recurrent heart failure in patients with chronic heart failure: a cohort study. Arq Bras Cardiol 2019;113:197\u2013204. https:\/\/doi.org\/10.5935\/abc.20190120; PMID: 31340235. DOI: 10.5935\/abc.20190120","DOI":"10.5935\/abc.20190120"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Zhang B, Xu Y, Huang X, et al. Lipoprotein(a) as a novel biomarker for predicting adverse outcomes in ischemic heart failure. Front Cardiovasc Med 2024;11:1466146. https:\/\/doi.org\/10.3389\/fcvm.2024.1466146; PMID: 39301496. DOI: 10.3389\/fcvm.2024.1466146","DOI":"10.3389\/fcvm.2024.1466146"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Zhang W, Speiser JL, Ye F, et al. High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis. J Am Coll Cardiol 2021;78:1083\u201394. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.016; PMID: 34503676. DOI: 10.1016\/j.jacc.2021.07.016","DOI":"10.1016\/j.jacc.2021.07.016"},{"key":"ref65","unstructured":"Yadalam AK, Gangavelli A, Razavi AC, et al. Lipoprotein(a) levels and adverse outcomes in heart failure. J Card Fail 2025:S1071-9164(25)00160-5. https:\/\/doi.org\/10.1016\/j.cardfail.2025.03.016; PMID: 40189094."},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Filtz A, Shapiro MD, Whelton PK, et al. Evolving strategies in cardiovascular disease prevention: 2025 American society for preventive cardiology highlights. Am J Prev Cardiol 2025;24:101357. https:\/\/doi.org\/10.1016\/j.ajpc.2025.101357; PMID: 41404186. DOI: 10.1016\/j.ajpc.2025.101357","DOI":"10.1016\/j.ajpc.2025.101357"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Mapelli M, Rubbo FM, Costantino S, et al. Pharmacological therapy of HFrEF in 2025: navigating new advances and old unmet needs in an eternal balance between progress and perplexities. Card Fail Rev 2025;11:e18. https:\/\/doi.org\/10.15420\/cfr.2024.37; PMID: 40771308. DOI: 10.15420\/cfr.2024.37","DOI":"10.15420\/cfr.2024.37"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Tan J, Xu W, Hu S, et al. Genetic evidence linking lipoprotein(a) to cardiovascular disease and the potential role of aspirin: a Mendelian randomization study. Rev Cardiovasc Med 2025;26:39322. https:\/\/doi.org\/10.31083\/RCM39322; PMID: 41209110. DOI: 10.31083\/RCM39322","DOI":"10.31083\/RCM39322"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Emanuelsson F, Jensen J, Omar M, et al. Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and Simple. J Clin Lipidol 2024;19:276\u201385. https:\/\/doi.org\/S1933-2874(24)00303-9. https:\/\/doi.org\/10.1016\/j.jacl.2024.12.015; PMID: 39843293. DOI: 10.1016\/j.jacl.2024.12.015","DOI":"10.1016\/j.jacl.2024.12.015"},{"key":"ref70","unstructured":"Bittner VA, Szarek M, Aylward PE, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 2020;75:133\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.057; PMID: 31948641."},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2012;125:241\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.045120; PMID: 22128224. DOI: 10.1161\/CIRCULATIONAHA.111.045120","DOI":"10.1161\/CIRCULATIONAHA.111.045120"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063; PMID: 35363499. DOI: 10.1161\/CIR.0000000000001073","DOI":"10.1161\/CIR.0000000000001073"},{"key":"ref73","unstructured":"de Boer LM, Oorthuys AOJ, Wiegman A, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol 2022;29:779\u201392. https:\/\/doi.org\/10.1093\/eurjpc\/zwab171; PMID: 34849724."},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Rivera FB, Cha SW, Linnaeus Louisse C, et al. Impact of proprotein convertase subtilisin\/Kexin Type 9 inhibitors on lipoprotein(a): a meta-analysis and meta-regression of randomized controlled trials. JACC Adv 2025;4:101549. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101549; PMID: 39877671. DOI: 10.1016\/j.jacadv.2024.101549","DOI":"10.1016\/j.jacadv.2024.101549"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. J Am Coll Cardiol 2019;73:3210\u201327. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.004; PMID: 30423394. DOI: 10.1016\/j.jacc.2018.11.004","DOI":"10.1016\/j.jacc.2018.11.004"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014;114:711\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2014.05.060; PMID: 25060413. DOI: 10.1016\/j.amjcard.2014.05.060","DOI":"10.1016\/j.amjcard.2014.05.060"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014;63:1278\u201388. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.006; PMID: 24509273. DOI: 10.1016\/j.jacc.2014.01.006","DOI":"10.1016\/j.jacc.2014.01.006"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Safarova MS, Kullo IJ. Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors. Atherosclerosis 2022;361:30\u20131. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.10.010; PMID: 36344291. DOI: 10.1016\/j.atherosclerosis.2022.10.010","DOI":"10.1016\/j.atherosclerosis.2022.10.010"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Bayes-Genis A, Lup\u00f3n J, Revuelta-Lopez E, et al. Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: the EVO-HF trial. Eur J Heart Fail 2023;25:1439\u201343. https:\/\/doi.org\/10.1002\/ejhf.2932; PMID: 37323111. DOI: 10.1002\/ejhf.2932","DOI":"10.1002\/ejhf.2932"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019;139:1483\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184; PMID: 30586750. DOI: 10.1161\/CIRCULATIONAHA.118.037184","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 2022;146:1109\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620; PMID: 36031810. DOI: 10.1161\/CIRCULATIONAHA.122.061620","DOI":"10.1161\/CIRCULATIONAHA.122.061620"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174; PMID: 30403574. DOI: 10.1056\/NEJMoa1801174","DOI":"10.1056\/NEJMoa1801174"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"White HD, Schwartz GG, Szarek M, et al. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J 2022;43:1554\u201365. https:\/\/doi.org\/10.1093\/eurheartj\/ehab804; PMID: 34922353. DOI: 10.1093\/eurheartj\/ehab804","DOI":"10.1093\/eurheartj\/ehab804"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Nissen SE, Ni W, Shen X, et al. Lepodisiran \u2013 a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med 2025;392:1673\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2415818; PMID: 40162643. DOI: 10.1056\/NEJMoa2415818","DOI":"10.1056\/NEJMoa2415818"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"O\u2019Donoghue ML, Rosenson RS, L\u00f3pez JAG, et al. The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-DOSE extension period results. J Am Coll Cardiol 2024;84:790\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.058; PMID: 39168564. DOI: 10.1016\/j.jacc.2024.05.058","DOI":"10.1016\/j.jacc.2024.05.058"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Nissen SE, Wang Q, Nicholls SJ, et al. Zerlasiran\u2013a small-interfering RNA targeting lipoprotein(a): a Phase 2 randomized clinical trial. JAMA 2024;332:1992\u20132002. https:\/\/doi.org\/10.1001\/jama.2024.21957; PMID: 39556769. DOI: 10.1001\/jama.2024.21957","DOI":"10.1001\/jama.2024.21957"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals (Basel) 2023;16:577. https:\/\/doi.org\/10.3390\/ph16040577; PMID: 37111334. DOI: 10.3390\/ph16040577","DOI":"10.3390\/ph16040577"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020;382:244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239; PMID: 31893580. DOI: 10.1056\/NEJMoa1905239","DOI":"10.1056\/NEJMoa1905239"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Nicholls SJ, Ni W, Rhodes GM, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA 2025;333:222\u201331. https:\/\/doi.org\/10.1001\/jama.2024.24017; PMID: 39556768. DOI: 10.1001\/jama.2024.24017","DOI":"10.1001\/jama.2024.24017"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/10.15420\/cfr.2025.46","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:31:23Z","timestamp":1776940283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":90,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.46","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"e07"}}